Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Cardio-Oncology
When should you consider prescribing dexarazoxane for patients on anthracyclines?
Related Questions
How would you approach warfarin management in patients with mechanical aortic valve and atrial fibrillation, if they develop chemotherapy-related severe thrombocytopenia?
In patients with moderate calcific mitral stenosis, possible HFpEF and dyspnea on exertion, how would you differentiate the etiology of the symptoms?
What is your preferred diagnostic approach to suspected immune checkpoint inhibitor cardiotoxicity in patients who are otherwise not clinically stable enough for cMRI?
How do you advise patients on cardiotoxicity when they are expected to receive a low mean heart dose and low cardiac substructure doses with their radiation plan?
In a patient with cardiac light chain amyloid who has significant heart failure symptoms, including inotrope dependence at presentation, how much clinical benefit does treatment provide?
How would you counsel non-cardiologists needing to prescribe a QTc prolonging medication in a patient with an EKG showing prolonged QTc but no history of long QTc syndrome and no known cardiomyopathy?
Similar to the HFA-ICOS risk stratification tool for patients on chemotherapy, are there cardiac risk calculators available for use in patients starting immunotherapy?
What would be a reasonable next-step approach to the evaluation of mild LV systolic dysfunction with regional wall motion abnormalities on TTE in a patient receiving carboplatin/paclitaxel for ovarian cancer without any cardiac symptoms?
What are your first-line vasopressors of choice for the management of acute severe aortic regurgitation and persistent hypotension/shock?
What is your risk/benefit analysis when deciding on the appropriateness and timing for discontinuation of systemic anticoagulation in patients who underwent ablation for paroxysmal atrial fibrillation with CHADS2VASc score >2?
